ARQ 501 in Combination With Docetaxel in Patients With Cancer

Inclusion Criteria: * Have a histologically or cytologically confirmed diagnosis of a locally advanced or metastatic carcinoma. (Patients may have either measurable or nonmeasurable disease.) * Be ≥18 years old. * Must not be eligible for therapy of higher curative potential. * Have a Karnofsky Performance Status (KPS) of ≥70%. * Have an estimated life expectancy of ≥12 weeks. * Be male or non-pregnant, non-lactating female patients. Patients who are fertile agree to use an effective barrier method of birth control (e.g., latex condom, diaphragm, or cervical cap) to avoid pregnancy. * Have a negative serum or urine pregnancy test within 7 days prior to the first dose of study drug (if patient is a female of childbearing potential). * Sign a written informed consent document. * Have adequate organ function as determined per protocol defined laboratory value Exclusion Criteria: * Have received previous treatment with ARQ 501. * Have an active, uncontrolled systemic infection considered opportunistic, life threatening, or clinically significant at the time of treatment. * Are pregnant or lactating. * Have a psychiatric disorder(s) that would interfere with consent, study participation, or follow-up. * Have received any chemotherapy, immunotherapy, vaccines, monoclonal antibodies, major surgery, or irradiation, whether conventional or investigational, within 2 weeks of treatment in this study. * Have not recovered from acute toxicity of all previous therapy prior to enrollment. * Have any other severe concurrent disease, which, in the judgment of the investigator, would make the patient inappropriate for entry into this study. * Have symptomatic or untreated central nervous system (CNS) metastases. * Have a known severe hypersensitivity to docetaxel or drugs formulated with polysorbate 80.